Join
Live feed
·
PRReleasevia Quantisnow
Anixa Biosciences Inc. logo

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

ByQuantisnow·Wall Street's wire, on your screen.
ANIX· Anixa Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANIX (Anixa Biosciences Inc.) and more on Quantisnow.